biostudies-literatureUnknown21(1)Booth SWOxford Experimental Cancer Centre<h4>Background</h4>This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients with relapsed / refractory lymphoma or advanced solid organ cancers and to assess HR23B protein expression by immunohistochemistry as a biomarker of HDAC inhibitor sensitivity.<h4>Methods</h4>Patients with advanced solid-organ cancers with high HR23B expression or lymphomas received CXD101 at the recommended phase 2 dose (RP2D). Key exclusions: corrected QT > 450 ms, neutrophils < 1.5 × 10⁹/L, platelets < 75 × 10⁹/L, ECOG > 1. Baseline HR23B expression was assessed by immunohistochemistry.<h4>Results</h4>Fifty-one patients enrolled between MarchBMC cancer851https://www.ebi.ac.uk/biostudies/studies/S-EPMC8306282biostudies-literatureA Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.PMC8306282Rees GKazmi FCampo LSoilleux EKesavan MLa Thangue NWhittaker JBooth SWCollins GPRoyston DHildyard CEyre TAMiddleton MRKerr DWang LMfalseA Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.<h4>Background</h4>This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients with relapsed / refractory lymphoma or advanced solid organ cancers and to assess HR23B protein expression by immunohistochemistry as a biomarker of HDAC inhibitor sensitivity.<h4>Methods</h4>Patients with advanced solid-organ cancers with high HR23B expression or lymphomas received CXD101 at the recommended phase 2 dose (RP2D). Key exclusions: corrected QT > 450 ms, neutrophils < 1.5 × 10⁹/L, platelets < 75 × 10⁹/L, ECOG > 1. Baseline HR23B expression was assessed by immunohistochemistry.<h4>Results</h4>Fifty-one patients enrolled between March2021-01-01T00:00:00Z2021 Jul2026-05-07T23:54:55.056Z2022-02-11T00:20:49.253ZS-EPMC83062823430122110.1186/s12885-021-08595-w